Search Within

Samuel Aaron Funt

  1. "Biostatistics Service"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (20)
Groups
  1. Biostatistics Service (47)
  2. Department of Medicine (47)
  3. Epidemiology and Biostatistics (47)
  4. Genitourinary Oncology Service (47)
  5. Solid Tumor Oncology Division (47)
  6. Weinberg Fellows (47)

More Groups

People
  1. Dean Bajorin (43)
  2. Jonathan Rosenberg (32)
  3. Gopakumar Iyer (31)
  4. Irina Ostrovnaya (27)
  5. Min Yuen Teo (25)
  6. Hikmat Al-Ahmadie (24)

More People

Years
  1. 2024 (8)
  2. 2023 (3)
  3. 2022 (6)
  4. 2021 (11)
  5. 2020 (6)
  6. 2019 (5)

More Years

Publications
  1. Journal of Clinical Oncology (32)
  2. JCO Precision Oncology (2)
  3. Annals of Oncology (1)
  4. Annals of Surgery (1)
  5. Annals of Thoracic Surgery (1)
  6. British Journal of Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (34)
  2. Elsevier Science, Inc. (2)
  3. Lippincott Williams & Wilkins (2)
  4. Nature Publishing Group (2)
  5. Oxford University Press (2)
  6. Wiley Blackwell (2)

More Publishers

Results (47)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Meeting Abstract

    Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Detailed evaluation of hearing loss (HL) associated with high-dose (HD) carboplatin for salvage treatment of germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Knezevic, A.; Wilson, K.; Bromberg, M.; Budnick, A.; McHugh, D. J.; Larsen, E.; Bajorin, D. F.; Motzer, R. J.; Tonorezos, E. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer
    Meeting Abstract

    Cha, E. K.; Iyer, G.; Funt, S. A.; Regazzi, A. M.; Francis, J.; Heinemann, M. H.; Ostrovnaya, I.; Dalbagni, G.; Bajorin, D. F.; Bochner, B. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Adjuvant chemotherapy with etoposide plus cisplatin for patients with pathologic stage II nonseminomatous germ cell tumors
    Journal Article

    McHugh, D. J.; Funt, S. A.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)
    Meeting Abstract

    Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J. S.; Patil, S.; Reuter, V. E.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Milowsky, M. I.; Appleman, L. J.; Dorff, T. B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Keegan, N. M.; Funt, S. A.; Kania, B. E.; Iyer, G.; Clement, J. M.; McCoy, A. S.; Hettich, G.; Ziv, E.; Maher, C. A.; Nair, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Impact of teratoma on the cumulative incidence of disease-related death in patients with advanced germ cell tumors
    Journal Article

    Funt, S. A.; Patil, S.; Feldman, D. R.; Motzer, R. J.; Bajorin, D. F.; Sheinfeld, J.; Tickoo, S. K.; Reuter, V. E.; Bosl, G. J.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT)
    Meeting Abstract

    McHugh, D. J.; Funt, S.; Silber, D.; Knezevic, A.; Patil, S.; O'Donnell, D.; Tsai, S.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save